S. 5297, Pharmaceutical Supply-Chain Study. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
S. 5297 · Mixed
What it does
This bill requires the Centers for Medicare & Medicaid Services (CMS) to study and report on how it could use its power to set drug prices and coverage rules to boost domestic production of pharmaceutical ingredients and reduce U.S. reliance on foreign suppliers. The report may recommend price floors to protect domestic manufacturers and prioritizing U.S.-made ingredients in Medicare/Medicaid coverage decisions.
The analysis names domestic pharmaceutical manufacturers — and 2 more groups — among the beneficiaries.
The trade-off
If CMS implements price floors based on this report, Medicare/Medicaid reimbursement rates could rise, increasing federal drug spending and potentially shifting costs to beneficiaries through higher copays or reduced coverage.
Transparency scores 75%, with a medium warning level and no provisions unrelated to the bill's subject.
Who is behind it
Filed by Adam Schiff. Cosponsored by Rick Scott.